Výsledky vyhledávání - "James, Zwiebel A."

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Publikováno v: Clinical Cancer Research. 29:1477-1483

Purpose: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0deaba3a14fb4dcac6730d29e90dbb46
https://doi.org/10.1158/1078-0432.ccr-22-2150

Zobrazit plný text záznamu

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Representativeness of Study Participants

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93e238d00836438710bd3e04e5688eb2
https://doi.org/10.1158/1078-0432.22633064.v1

Zobrazit plný text záznamu

Data from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Purpose:Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2562eea6433e82a479a4864ae9520a
https://doi.org/10.1158/1078-0432.c.6533050.v1

Zobrazit plný text záznamu

Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients

Autor: Natalie Gahres, James Zwiebel, Christopher D. Gocke, Robert G. Fenton, Olga Goloubeva, Barry Meisenberg, Aaron P. Rapoport, Meyer Heyman, Bashi Ratterree, Jodi A. Flaws, Dragana Tomic, Naoko Takebe, Ashraf Z. Badros, Bin Zhang, Howard Streicher

Publikováno v: Journal of Clinical Oncology. 23:4089-4099

PurposeBcl-2 regulates the mitochondrial apoptosis pathway that promotes chemotherapy resistance. Bcl-2 antisense oligonucleotide, G3139, targets Bcl-2 mRNA.Patients and MethodsG3139 was administered (3 to 7 mg/kg/d for 7 days) by continuous intraven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78aefc26ad7bbae47b5c6f1831eb13e1
https://doi.org/10.1200/jco.2005.14.381

Zobrazit plný text záznamu

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

Autor: Judith E, Karp, Ivana, Gojo, Roberto, Pili, Christopher D, Gocke, Jacqueline, Greer, Chuanfa, Guo, David, Qian, Lawrence, Morris, Michael, Tidwell, Helen, Chen, James, Zwiebel

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 10(11)

Vascular endothelial growth factor (VEGF) promotes acute myelogenous leukemia (AML) cell growth and survival and may contribute to drug resistance. bevacizumab, an anti-VEGF monoclonal antibody, exhibits clinical activity against diverse malignancies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::120d0cc52e53cd9ad1d86a46dd6ac65e
https://pubmed.ncbi.nlm.nih.gov/15173063

Zobrazit plný text záznamu

Clinical applications of p53-directed gene therapy

Autor: Della Makower, Jian You Tan, Morris Edelman, James Zwiebel, Howard Kaufman, Alla M. Rozenblit, Bo Yu, Maureen E. Lane, Scott Wadler

Publikováno v: I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]. 1(6)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb2d5a67a372f7e6821c9856b0c73a35
https://pubmed.ncbi.nlm.nih.gov/12658897

Zobrazit plný text záznamu

Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies

Autor: Della, Makower, Alla, Rozenblit, Howard, Kaufman, Morris, Edelman, Maureen E, Lane, James, Zwiebel, Hilda, Haynes, Scott, Wadler

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 9(2)

ONYX-015 is a genetically modified adenovirus with a deletion of the E1B early gene and is therefore designed to replicate preferentially in p53-mutated cells. A Phase II trial of intralesional ONYX-015 was conducted in patients with hepatobiliary tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::81cca247ad1f2e5227c6c6a3838af8a8
https://pubmed.ncbi.nlm.nih.gov/15814661

Zobrazit plný text záznamu

Akademický článek

Phase II trial of fenretinide in advanced renal carcinoma.

Autor: Ulka Vaishampayan, Lance K. Heilbrun, Ralph E. Parchment, Vikash Jain, James Zwiebel, Ramesh R. Boinpally, Patricia LoRusso, Maha Hussain

Publikováno v: Investigational New Drugs; Jan2005, Vol. 23 Issue 2, p179-185, 7p

Zobrazit plný text záznamu

Akademický článek

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study.

Autor: Kirschbaum, Mark H., Zain, Jasmine M., Popplewell, Leslie, Pullarkat, Vinod, Nademanee, Auayporn P., Delioukina, Maria L., Pulone, Bernadette ^*, Matsuoka, Deron ^*, Frankel, Paul ^*, James, Zwiebel A., Forman, Stephen J., Newman, Edward ^*, Gandara, David ^*

Publikováno v: In Blood 16 November 2007 110(11):2568-2568

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání